Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eriko Kinugasa

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
American Journal of Nephrology|January 14, 2010
Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidismChiaki Kumata, Masahide Mizobuchi, Hiroaki Ogata, et al.
Nephrology (Carlton, Vic.)|March 12, 2004
Management of secondary hyperparathyroidism of dialysis patientsTadao Akizawa, Motohiro Kamimura, Masahide Mizobuchi, et al.
American Journal of Nephrology|July 28, 2011
Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progressionMasahide Mizobuchi, Hiroaki Ogata, Nozomu Hosaka, et al.
Clinical Calcium|November 8, 2005
[Apoptosis: a possible mechanism of suppressing parathyroid hyperplasia by calcimimetics]Masahide Mizobuchi, Fumie Saji, Kazuhiro Shiizaki, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 31, 2012
Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-αYumie Aoshima, Masahide Mizobuchi, Hiroaki Ogata, et al.
Clinical and Experimental Nephrology|June 7, 2013
Correction of hyperphosphatemia suppresses cardiac remodeling in uremic ratsAi Yamazaki-Nakazawa, Masahide Mizobuchi, Hiroaki Ogata, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|November 4, 2014
Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidismTadao Akizawa, Takashi Akiba, Hideki Hirakata, et al.
Clinical and Experimental Nephrology|March 23, 2021
Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical studyEriko Kinugasa, Ken Igawa, Hisaki Shimada, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|November 16, 2005
[Serum amyloid protein A was a useful marker for steroid tapering in a case of MPO-ANCA-associated vasculitis]Yusuke Shikama, Kazuyuki Kuriu, Yasuhiro Shibuya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
New strategies for the treatment of secondary hyperparathyroidismTadao Akizawa, Kazuhiro Shiizaki, Ikuji Hatamura, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
American Journal of Nephrology|January 14, 2010
Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidismChiaki Kumata, Masahide Mizobuchi, Hiroaki Ogata, et al.
Nephrology (Carlton, Vic.)|March 12, 2004
Management of secondary hyperparathyroidism of dialysis patientsTadao Akizawa, Motohiro Kamimura, Masahide Mizobuchi, et al.
American Journal of Nephrology|July 28, 2011
Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progressionMasahide Mizobuchi, Hiroaki Ogata, Nozomu Hosaka, et al.
Clinical Calcium|November 8, 2005
[Apoptosis: a possible mechanism of suppressing parathyroid hyperplasia by calcimimetics]Masahide Mizobuchi, Fumie Saji, Kazuhiro Shiizaki, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 31, 2012
Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-αYumie Aoshima, Masahide Mizobuchi, Hiroaki Ogata, et al.
Clinical and Experimental Nephrology|June 7, 2013
Correction of hyperphosphatemia suppresses cardiac remodeling in uremic ratsAi Yamazaki-Nakazawa, Masahide Mizobuchi, Hiroaki Ogata, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|November 4, 2014
Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidismTadao Akizawa, Takashi Akiba, Hideki Hirakata, et al.
Clinical and Experimental Nephrology|March 23, 2021
Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical studyEriko Kinugasa, Ken Igawa, Hisaki Shimada, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|November 16, 2005
[Serum amyloid protein A was a useful marker for steroid tapering in a case of MPO-ANCA-associated vasculitis]Yusuke Shikama, Kazuyuki Kuriu, Yasuhiro Shibuya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
New strategies for the treatment of secondary hyperparathyroidismTadao Akizawa, Kazuhiro Shiizaki, Ikuji Hatamura, et al.
Pageof 5